Arrowhead Bolsters Plozasiran Case With 2-Year Trial Data

Edgen Stock

·Mar 28 2026, 14:50

Share to

Share to

Copy link

Key Takeaways

Arrowhead Pharmaceuticals presented positive long-term safety and efficacy data for its investigational cholesterol drug, plozasiran, significantly strengthening its profile ahead of potential regulatory review. The results from a two-year study were unveiled at a major cardiology conference, boosting investor outlook on the drug's path to market.

Arrowhead Pharmaceuticals presented positive two-year, long-term data for its drug candidate plozasiran on March 28, 2026.
The study confirmed the efficacy and safety of plozasiran for a broad spectrum of patients with hypertriglyceridemia (HTG).
Positive long-term results de-risk the asset for investors and increase the probability of regulatory approval, strengthening Arrowhead's market position.

Plozasiran Shows Sustained Efficacy in Two-Year Study

Arrowhead Pharmaceuticals presented significant long-term clinical data for its investigational drug, plozasiran, on March 28, 2026. The findings, sourced from a two-year open-label extension study, demonstrated sustained efficacy and a favorable safety profile for patients with hypertriglyceridemia (HTG). The data was formally presented by Dr. Christie M. Ballantyne of Baylor College of Medicine at the American College of Cardiology's 75th Annual Scientific Session and Expo, a key event for cardiovascular research.

Positive Data De-Risks Path to Market Approval

These long-term results provide critical validation for plozasiran as a potential therapeutic solution, significantly de-risking the asset from an investment perspective. By establishing a consistent safety and efficacy record over a two-year period, Arrowhead has strengthened its case for future regulatory submissions. For investors in Arrowhead (NASDAQ: ARWR), this milestone increases the perceived probability of market approval and successful commercialization, potentially solidifying the company's footing in the competitive cardiovascular drug market.